Ascendis Pharma A/S (ASND): Price and Financial Metrics

Ascendis Pharma A/S (ASND): $107.69

1.11 (-1.02%)

POWR Rating

Component Grades








Add ASND to Watchlist
Sign Up

Industry: Biotech




#172 of 347

in industry

ASND Price/Volume Stats

Current price $107.69 52-week high $127.77
Prev. close $108.80 52-week low $64.33
Day low $106.49 Volume 1,471,600
Day high $111.41 Avg. volume 465,425
50-day MA $93.56 Dividend yield N/A
200-day MA $93.62 Market Cap 6.21B

ASND Stock Price Chart Interactive Chart >

Ascendis Pharma A/S (ASND) Company Bio

Ascendis Pharma A/S is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs. The company was founded in 2006 and is based in Hellerup, Denmark.

ASND Latest News Stream

Event/Time News Detail
Loading, please wait...

ASND Latest Social Stream

Loading social stream, please wait...

View Full ASND Social Stream

Latest ASND News From Around the Web

Below are the latest news stories about ASCENDIS PHARMA A that investors may wish to consider to help them evaluate ASND as an investment opportunity.

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

– Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan – Ascendis Pharma is eligible to receive $70 million upfront, development/regulatory milestones of up to $175 million, transfer pricing, and commercial milestones – Ascendis Pharma is also eligible to receive royalties on net sales in Japan, of up to mid-20’s percent, varying by product COPENHAGEN, Denmark, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasd

Yahoo | November 29, 2023

Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism

- YORVIPATH (developed as TransCon PTH) is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism - Ascendis plans its first EU launch of YORVIPATH in Germany in January 2024 COPENHAGEN, Denmark, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Commission (EC) has granted marketing authorization for YORVIPATH® (palopegteriparatide) as replacement therapy indicated for the treatmen

Yahoo | November 20, 2023

Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA

COPENHAGEN, Denmark, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has resubmitted its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adults with hypoparathyroidism to the U.S. Food & Drug Administration (FDA). The resubmission follows the Type A meeting held with the FDA in late August. “Research has shown that parathyroid hormone (PTH) replacement therapy is the ideal treatment for patients living with the s

Yahoo | November 15, 2023

Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript

Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript November 7, 2023 Ascendis Pharma A/S misses on earnings expectations. Reported EPS is $-2.88 EPS, expectations were $-2.63. Operator: Hello, and welcome to Ascendis Pharma Third Quarter 2023 Earnings Conference Call and Webcast. Following the prepared remarks, there will be a question-and-answer period, instructions will be […]

Yahoo | November 8, 2023

Ascendis Pharma Reports Third Quarter 2023 Financial Results

European Commission decision for TransCon™ PTH expected this month; if approved, first European Union launch planned in Germany in January 2024TransCon PTH NDA resubmission to FDA expected before mid-NovemberCompleted enrollment in the Phase 3 ApproaCH Trial; initiated TransCon CNP infant trial in the third quarter 2023; expect to initiate combination trial of TransCon CNP and TransCon hGH in the fourth quarter 2023 SKYTROFA Q3 revenue of €47.0 million, increasing full year 2023 SKYTROFA revenue

Yahoo | November 7, 2023

Read More 'ASND' Stories Here

ASND Price Returns

1-mo 16.97%
3-mo 10.36%
6-mo 15.49%
1-year -8.01%
3-year -38.04%
5-year 70.94%
YTD -11.82%
2022 -9.22%
2021 -19.34%
2020 19.88%
2019 122.06%
2018 56.39%

Continue Researching ASND

Want to see what other sources are saying about Ascendis Pharma A's financials and stock price? Try the links below:

Ascendis Pharma A (ASND) Stock Price | Nasdaq
Ascendis Pharma A (ASND) Stock Quote, History and News - Yahoo Finance
Ascendis Pharma A (ASND) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!